Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282256 · ClinicalTrials.gov registry record · Phase 2
A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00282256 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 19 participants.
The verdict
NCT00282256, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
A study to assess the pharmacokinetics, safety and effectiveness of tacrolimus in stable pediatric liver transplant patients converted from a Prograf® based immunosuppression regimen to a modified release tacrolimus based immunosuppression regimen.
Interventions
- DRUG tacrolimus
- DRUG tacrolimus modified release (MR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282256
The ClinicalTrials.gov registry entry for NCT00282256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tacrolimus is the first listed.
NCT00282256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282256 about?
NCT00282256 is a clinical study titled "A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients". A study to assess the pharmacokinetics, safety and effectiveness of tacrolimus in stable pediatric liver transplant patients converted from a Prograf® based immunosuppression regimen to a modified release tacrolimus based immunosuppression regimen.
What is the current status of trial NCT00282256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2004-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00282256?
The interventions under investigation include: tacrolimus (DRUG), tacrolimus modified release (MR) (DRUG).
Who is sponsoring clinical trial NCT00282256?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.